Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-CD19CD20-ALLO1 in Patients With Multiple Sclerosis
NCT07008378Phase 1Active, not recruiting
- Sponsor
- Genentech
- Start
- Oct 2025
- Primary completion
- Aug 2032
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of P-CD19CD20-ALLO1 in multiple sclerosis (MS), sponsored by Genentech. Primary endpoints: Number of Participants With Dose-limiting Toxicity and Number of Participants With Adverse Events up to 5 years. Started Oct 2025; status: active, not recruiting.
02
Drugs
P-CD19CD20-ALLO1
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07008378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07008378.